Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27673970 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1020672 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL17180364 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL8342239 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL5128225 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL3391831 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL3397461 | 1.00 | CYP1A2 (0.51) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL30476413 | 0.87 | ANPEP (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL8328572 | 0.87 | CHRM2 (0.41) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL7883874 | 0.87 | ANPEP (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747250-A1 | KINASE INHIBITORS | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025019585-A1 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-23 | — | — | WO | disclosed |
| US-10112956-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2933247-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20170197983-A1 | HETEROCYCLIC COMPOUNDS HAVING CHOLESTEROL 24-HYDROXYLASE ACTIVITY | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9643957-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2933247-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | CYP1A2 1011/4885POLB 2486/4885CYP3A4 1048/4885 |
| US-10112956-B2 | Heterocyclic compounds having cholesterol 24-hydroxylase activity | CYP46A1, CYP27A1, NCEH1 | CYP1A2 71/4885POLB 4494/4885CYP3A4 65/4885 |
| US-20170197983-A1 | HETEROCYCLIC COMPOUNDS HAVING CHOLESTEROL 24-HYDROXYLASE ACTIVITY | CYP46A1, CYP27A1, NCEH1 | CYP1A2 71/4885POLB 4494/4885CYP3A4 65/4885 |
| US-20150315209-A1 | HETEROCYCLIC COMPOUND | HCN4, KCNH1, SCN4A | CYP1A2 836/4885POLB 4606/4885CYP3A4 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.